Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01454284
Registration number
NCT01454284
Ethics application status
Date submitted
14/10/2011
Date registered
18/10/2011
Date last updated
17/04/2018
Titles & IDs
Public title
A Study in Participants With Type I Diabetes Mellitus
Query!
Scientific title
The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 1 Diabetes Mellitus Treated With Preprandial Insulin Lispro: a Double-Blind, Randomized, 52-week Study
Query!
Secondary ID [1]
0
0
I2R-MC-BIAO
Query!
Secondary ID [2]
0
0
12147
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
IMAGINE 3
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Diabetes Mellitus, Type 1
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Glargine
Treatment: Drugs - LY2605541
Treatment: Drugs - Insulin Lispro
Experimental: LY2605541 + Insulin Lispro - LY2605541 titrated based on blood glucose readings, administered subcutaneously (SC) once daily at bedtime for 52 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered SC at meal times for 52 weeks.
Active Comparator: Glargine + Insulin Lispro - Glargine dose titrated based on blood glucose readings, administered SC once daily at bedtime for 52 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered SC at meal times for 52 weeks.
Treatment: Drugs: Glargine
Treatment: Drugs: LY2605541
Treatment: Drugs: Insulin Lispro
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Hemoglobin A1c (HbA1c)
Query!
Assessment method [1]
0
0
HbA1c is a test that measures a participant's average blood glucose level over a 2 to 3 month timeframe. Least squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, stratification factors (country, baseline low density lipoprotein cholesterol [LDL-C] [<100 milligrams/deciliter (mg/dL) (2.6 millimoles/liter [mmol/L]) and =100 mg/dL (2.6 mmol/L)], baseline prior basal insulin therapy [insulin glargine/detemir/other]), visit, treatment-by-visit interaction, and baseline HbA1c as the fixed effects and participant as the random effect.
Query!
Timepoint [1]
0
0
52 weeks
Query!
Secondary outcome [1]
0
0
Hemoglobin A1c (HbA1c)
Query!
Assessment method [1]
0
0
HbA1c is a test that measures a participant's average blood glucose level over the past 2 to 3 months. LS means were calculated using MMRM adjusting for treatment, stratification factors (country, baseline LDL-C [<100 mg/dL (2.6 mmol/L) and =100 mg/dL (2.6 mmol/L)], baseline prior basal insulin therapy [insulin glargine/detemir/other]), visit, treatment-by-visit interaction, and baseline HbA1c as the fixed effects and participant as the random effect.
Query!
Timepoint [1]
0
0
26 weeks
Query!
Secondary outcome [2]
0
0
Change From Baseline to 52 Weeks in HbA1c
Query!
Assessment method [2]
0
0
HbA1c is a test that measures a participant's average blood glucose level over a 2 to 3 month timeframe. LS means were calculated using MMRM adjusting for treatment, stratification factors (country, baseline LDL-C [<100 mg/dL (2.6 mmol/L) and =100 mg/dL (2.6 mmol/L)], baseline prior basal insulin therapy [insulin glargine/detemir/other]), visit, treatment-by-visit interaction, and baseline HbA1c as the fixed effects and participant as the random effect.
Query!
Timepoint [2]
0
0
Baseline, 52 weeks
Query!
Secondary outcome [3]
0
0
Total Hypoglycemia Events
Query!
Assessment method [3]
0
0
Hypoglycemic episodes are defined as events which are associated with reported signs and symptoms of hypoglycemia and/or documented blood glucose (BG) concentrations of =70 mg/dL (3.9 mmol/L). Group mean rates of total hypoglycemia (per 30 days) are presented and were calculated from negative binomial regression models (number of episodes = treatment + baseline total hypoglycemia rate, with log [exposure in days/30] as an offset variable). Group mean is estimated by taking the inverse link function on individual participant covariates first and then averages over all participants.
Query!
Timepoint [3]
0
0
Baseline through 26 weeks, Baseline through 52 weeks
Query!
Secondary outcome [4]
0
0
Percentage of Participants With Total Hypoglycemic Events
Query!
Assessment method [4]
0
0
Hypoglycemic episodes are defined as events that are associated with the reported signs and symptoms of hypoglycemia and/or documented BG concentrations of =70 mg/dL (3.9 mmol/L). The percentage of participants was calculated by dividing the number of participants with hypoglycemic episodes by the total number of participants analyzed, multiplied by 100.
Query!
Timepoint [4]
0
0
Baseline through 26 weeks, Baseline through 52 weeks
Query!
Secondary outcome [5]
0
0
Percentage of Participants With HbA1c Equal to or Less Than 6.5% and Less Than 7.0%
Query!
Assessment method [5]
0
0
The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.
Query!
Timepoint [5]
0
0
up to 26 weeks, up to 52 weeks
Query!
Secondary outcome [6]
0
0
Percentage of Participants With HbA1c Less Than 7.0% and Without Nocturnal Hypoglycemia
Query!
Assessment method [6]
0
0
Hypoglycemic episodes are defined as events associated with reported signs and symptoms of hypoglycemia and/or a documented blood glucose concentration of =70 mg/dL (3.9 mmol/L). A nocturnal hypoglycemic event occurred between bedtime and waking and between the time points of 10:00 PM and 10:00 AM. The percentage of participants was calculated by dividing the number of participants with HbA1c <7.0% without nocturnal hypoglycemia by the total number of participants analyzed, multiplied by 100.
Query!
Timepoint [6]
0
0
up to 26 weeks, up to 52 weeks
Query!
Secondary outcome [7]
0
0
Nocturnal Hypoglycemia Rates
Query!
Assessment method [7]
0
0
Hypoglycemic episodes are defined as events that are associated with reported signs and symptoms of hypoglycemia and/or a documented BG concentration of =70 mg/dL (3.9 mmol/L). A nocturnal hypoglycemic event occurred between bedtime and waking and between the time points of 10:00 PM and 10:00 AM. Group mean rates of nocturnal hypoglycemia (per 30 days) are presented and were calculated from negative binomial regression models (number of episodes = treatment + baseline nocturnal hypoglycemia rate, with log [exposure in days/30] as an offset variable). Group mean is estimated by taking the inverse link function on individual participant covariates first and then averages over all participants.
Query!
Timepoint [7]
0
0
Baseline through 26 weeks, Baseline through 52 weeks
Query!
Secondary outcome [8]
0
0
Percentage of Participants With Nocturnal Hypoglycemic Events
Query!
Assessment method [8]
0
0
Hypoglycemic episodes are defined as events associated with the reported signs and symptoms of hypoglycemia and/or a BG concentration of =70 mg/dL (3.9 mmol/L). A nocturnal hypoglycemic event occurred between bedtime and waking and between the time points of 10:00 PM and 10:00 AM. The percentage of participants was calculated by dividing the number of participants with nocturnal hypoglycemic episodes by the total number of participants analyzed, multiplied by 100.
Query!
Timepoint [8]
0
0
Baseline through 26 weeks, Baseline through 52 weeks
Query!
Secondary outcome [9]
0
0
Change in Body Weight
Query!
Assessment method [9]
0
0
LS means were calculated using MMRM adjusting for treatment, stratification factors (baseline HbA1c [=8.5% and >8.5%], country, baseline LDL-C [<100 mg/dL (2.6 mmol/L) and =100 mg/dL (2.6 mmol/L)], baseline prior basal insulin therapy [insulin glargine/detemir/other]), visit, treatment-by-visit interaction, and baseline body weight as fixed effects and participant as the random effect.
Query!
Timepoint [9]
0
0
Baseline, 26 weeks, 52 weeks
Query!
Secondary outcome [10]
0
0
9 Point Self-monitored Blood Glucose (SMBG)
Query!
Assessment method [10]
0
0
9-point SMBG profiles were obtained over 2 days within the week prior to Weeks 0, 4, 12, 26, 39, and 52. SMBG measurements were taken at 9 time points: pre-morning meal, 2 hours post-morning meal, pre-midday meal, 2 hours post-midday meal, pre-evening meal, 2 hours post-evening meal, bedtime, at approximately 0300 hours, and the subsequent morning prior to the morning meal. LS means were calculated using MMRM adjusting for treatment, stratification factors (baseline HbA1c [=8.5% and >8.5%], country, baseline LDL-C [<100 mg/dL (2.6 mmol/L) and =100 mg/dL (2.6 mmol/L)], baseline prior basal insulin therapy [insulin glargine/detemir/other]), visit, treatment-by-visit interaction, and baseline BG values as the fixed effects and participant as the random effect.
Query!
Timepoint [10]
0
0
26 weeks and 52 weeks
Query!
Secondary outcome [11]
0
0
Fasting Serum Glucose (by Laboratory Measurement)
Query!
Assessment method [11]
0
0
Fasting serum glucose (FSG) is measured in blood before the morning meal. LS means were calculated using MMRM adjusting for treatment, stratification factors (baseline HbA1c [=8.5% and >8.5%], country, baseline LDL-C [<100 mg/dL (2.6 mmol/L) and =100 mg/dL (2.6 mmol/L)], baseline prior basal insulin therapy [insulin glargine/detemir/other]), visit, treatment-by-visit interaction, and baseline HbA1c as the fixed effects and participant as the random effect.
Query!
Timepoint [11]
0
0
26 weeks and 52 weeks
Query!
Secondary outcome [12]
0
0
Fasting Blood Glucose (by Participant Self Monitored Blood Glucose Readings)
Query!
Assessment method [12]
0
0
Fasting blood glucose (FBG) was measured by SMBG pre-morning meal. LS means were calculated using MMRM adjusting for treatment, stratification factors (baseline HbA1c [=8.5% and >8.5%], country, baseline LDL-C [<100 mg/dL (2.6 mmol/L) and =100 mg/dL (2.6 mmol/L)], baseline prior basal insulin therapy [insulin glargine/detemir/other]), visit, treatment-by-visit interaction, and baseline FBG as the fixed effects and participant as the random effect.
Query!
Timepoint [12]
0
0
26 weeks and 52 weeks
Query!
Secondary outcome [13]
0
0
Intra-participant Variability of Fasting Blood Glucose (FBG)
Query!
Assessment method [13]
0
0
FBG was measured by SMBG. Between-day glucose variability is measured by the standard deviation (SD) of FBG. LS means were calculated using MMRM adjusting for treatment, stratification factors (baseline HbA1c [=8.5% and >8.5%], country, baseline LDL-C [<100 mg/dL (2.6 mmol/L) and =100 mg/dL (2.6 mmol/L)], baseline prior basal insulin therapy [insulin glargine/detemir/other]), visit, treatment-by-visit interaction, and baseline SD of FBG as the fixed effects and participant as the random effect.
Query!
Timepoint [13]
0
0
26 weeks and 52 weeks
Query!
Secondary outcome [14]
0
0
0300 Hours Blood Glucose (BG) to Fasting BG Excursion
Query!
Assessment method [14]
0
0
Results of a 0300-hour to pre-morning meal (FBG) excursion are presented (only excursions within a single SMBG profile are included). LS means were calculated using MMRM adjusting for treatment, stratification factors (baseline HbA1c [=8.5% and >8.5%], country, baseline LDL-C [<100 mg/dL (2.6 mmol/L) and =100 mg/dL (2.6 mmol/L)], baseline prior basal insulin therapy [insulin glargine/detemir/other]), visit, treatment-by-visit interaction, and baseline excursion as the fixed effects and participant as the random effect.
Query!
Timepoint [14]
0
0
26 weeks and 52 weeks
Query!
Secondary outcome [15]
0
0
Triglycerides, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C), and Total Cholesterol
Query!
Assessment method [15]
0
0
Concentrations of cholesterol, HDL-C, and LDL-C, and triglycerides are presented. LS means were calculated using MMRM adjusting for stratification factors (baseline HbA1c [=8.5% and >8.5%], country, LDL-C [<100 mg/dL (2.6 mmol/L) and =100 mg/dL (2.6 mmol/L), except for the LDL-C outcome variable], prior basal insulin therapy [insulin glargine/detemir/other]), visit, treatment, treatment-by-visit interaction, and baseline value of corresponding lipid outcome variable as the fixed effects and participant as a random effect.
Query!
Timepoint [15]
0
0
26 weeks and 52 weeks
Query!
Secondary outcome [16]
0
0
Percentage of Participants With Change in Anti-LY2605541 Antibodies
Query!
Assessment method [16]
0
0
The percentage of participants with anti-LY2605541 treatment-emergent antibody response (TEAR) is summarized. TEAR is defined as change from baseline to post-baseline in the anti-LY2605541 antibody level either from undetectable to detectable, or from detectable to the value with at least 130% relative increase from baseline.
Query!
Timepoint [16]
0
0
26 weeks, 52 weeks
Query!
Secondary outcome [17]
0
0
Basal, Meal Time, and Total Insulin Dose Per Body Weight
Query!
Assessment method [17]
0
0
Basal insulin dose, meal-time insulin dose (short-acting bolus dose), and total insulin dose were calculated based on the dose during the last 7 days prior to the post-treatment visit or last 3 days prior to the randomization visit. LS means were calculated using a constrained Longitudinal Data Analysis (cLDA) model adjusting for indicator variables of each treatment group at each postbaseline visit and stratification variables (baseline HbA1c [=8.5% and> 8.5%], country, baseline LDL-C [<100 mg/dL (2.6 mmol/L) and =100 mg/dL (2.6 mmol/L)], and baseline prior basal insulin therapy [insulin glargine/detemir/ other]) as fixed effects.
Query!
Timepoint [17]
0
0
26 weeks and 52 weeks
Query!
Secondary outcome [18]
0
0
Insulin Treatment Satisfaction Questionnaire
Query!
Assessment method [18]
0
0
Insulin Treatment Satisfaction Questionnaire (ITSQ) is a validated measure containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. The questionnaire measures satisfaction from the following 5 domains: Convenience of Regimen, Lifestyle Flexibility, Glycemic Control, Hypoglycemic Control, and Insulin Delivery Device. Data are transformed to a scale of 0-100, where higher scores indicate better treatment satisfaction. LS means were calculated using an ANCOVA model adjusting for treatment, baseline HbA1c (=8.5% and >8.5%), country, and baseline prior basal insulin therapy (insulin glargine/detemir/other) as fixed effects and baseline ITSQ scores as a covariate.
Query!
Timepoint [18]
0
0
up to 52 weeks
Query!
Secondary outcome [19]
0
0
European Quality of Life -5 Dimension (EQ-5D-3L)
Query!
Assessment method [19]
0
0
The EQ-5D-3L is a generic, multidimensional, health-related, quality-of-life instrument. The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a three-level scale of 1-3 (no problem, some problems, and extreme problems). These combinations of attributes are converted into a weighted health-state Index Score according to the United States population-based algorithm. Scores range from -0.11 to 1.0, where a score of 1.0 indicates perfect health. LS means were calculated using an ANCOVA adjusting for treatment, baseline HbA1c (=8.5% and >8.5%), country, baseline prior basal insulin therapy (insulin glargine/detemir/other), and baseline EQ-5D-3L score as covariates.
Query!
Timepoint [19]
0
0
up to 52 weeks
Query!
Secondary outcome [20]
0
0
Adult Low Blood Sugar Survey
Query!
Assessment method [20]
0
0
Low Blood Sugar Survey (LBSS) (also referenced as Hypoglycemia Fear Survey - II [HFS-II]) is a questionnaire that measures 1) behaviors to avoid hypoglycemia and its negative consequences (15 items) and 2) worries about hypoglycemia and its negative consequences (18 items). Responses are made on a 5-point Likert-type scale where 0 = Never and 4 = Always. Total score is the sum of all items (range 0-132). Higher total scores reflect greater fear of hypoglycemia. LS means were calculated using MMRM adjusting for treatment, baseline HbA1c (=8.5% and >8.5%), country, baseline prior basal insulin therapy (insulin glargine/detemir/other), visit, treatment-by-visit interaction, and baseline LBSS score as the fixed effects and participant as the random effect.
Query!
Timepoint [20]
0
0
26 weeks and 52 weeks
Query!
Secondary outcome [21]
0
0
Rapid Assessment of Physical Activity (RAPA)
Query!
Assessment method [21]
0
0
The RAPA questionnaire assesses the level and intensity of physical activity of adult participants. It contains 2 subscales: RAPA 1 (Aerobic) and RAPA 2 (Strength and Flexibility). RAPA 1 contains 7 questions regarding the participant's amount and intensity of physical activity, allowing each participant's aerobic activity level to be categorized as sedentary, underactive, light activity, regular underactive, or active. RAPA 2 contains 2 questions regarding participants' physical activities that increase strength and improve flexibility. Each participant's strength and flexibility activity level is then categorized as neither strength nor flexibility activity, either strength or flexibility activity (not both), both strength and flexibility activity. The percentage of participants in each RAPA 1/2 category is presented and was calculated by dividing the number of participants in each RAPA 1/2 category by the total number of participants analyzed, multiplied by 100.
Query!
Timepoint [21]
0
0
52 weeks
Query!
Eligibility
Key inclusion criteria
- Type 1 diabetes for at least 1 year
- HbA1c value less than 12 percent according to the central laboratory at screening
- Body mass index of less than or equal to 35.0 kilograms per square meter (kg/m^2)
- Have been treated for at least 90 days prior to screening with
- insulin detemir, insulin glargine, or Neutral Protamine Hagedorn (NPH) in
combination with pre-meal insulin, or
- self-mixed or pre-mixed insulin regimens with any basal and bolus insulin
combination administered at least twice daily, or
- continuous SC insulin infusion therapy
- Women who are not breast feeding and test negative for pregnancy before receiving
treatment and agree to use reliable birth control until 2 weeks after last treatment
with study drug
- Are capable and willing to adhere to multiple daily injections, inject with a vial and
syringe and prefilled pen and perform self-monitored blood glucose (SMBG) readings and
record keeping
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Are using twice daily insulin glargine having been inadequately controlled on single
daily dose of glargine prior to screening
- Excessive insulin resistance defined as having received a total daily dose of insulin
greater than 1.5 units per kilogram (U/kg) at the time of randomization
- Receiving any oral or injectable medication (other than insulins or metformin for
treatment of polycystic ovarian disease) intended for the treatment of diabetes
mellitus in the 90 days prior to screening
- Lipid lowering medications:
- are using niacin preparations as lipid lowering medication and/or bile acid
sequestrants within 90 days prior to screening; or,
- are using lipid lowering medication at a dose that has not been stable for 90
days or more prior to screening
- Have fasting hypertriglyceridemia (defined as greater than 4.5 millimoles per liter
[mmol/L], greater than 400 milligrams per deciliter [mg/dL]) at screening, as
determined by the central laboratory.
- Have had more than 1 episode of severe hypoglycemia (defined as requiring assistance
due to neurologically disabling hypoglycemia) within 6 months prior to screening
- Have had 2 or more emergency room visits or hospitalizations due to poor glucose
control within 6 months prior to screening
- Have cardiac disease with functional status that is New York Heart Association Class
III or IV
- Have a history of renal transplantation or are currently receiving renal dialysis or
have serum creatinine greater than 2.5 mg/dL
- Have obvious clinical signs or symptoms of liver disease (excluding non-alcoholic
fatty liver disease [NAFLD]), acute or chronic hepatitis, non-alcoholic
steatohepatitis (NASH), or elevated liver enzyme measurements as indicated below:
- total bilirubin 2 times or more than the upper limit of normal (ULN) as defined
by the central laboratory, or
- alanine aminotransferase (ALT)/(serum glutamic pyruvic transaminase (SGPT) more
than 2.5 times ULN as defined by the central laboratory, or
- aspartate aminotransferase (AST)/(serum glutamic oxaloacetic transaminase (SGOT)
more than 2.5 times ULN as defined by the central laboratory
- Have active or untreated malignancy, have been in remission from clinically
significant malignancy (other than basal cell or squamous cell skin cancer) for less
than 5 years, or are at increased risk for developing cancer or a recurrence of cancer
- Diagnosed clinically significant diabetic autonomic neuropathy
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/01/2012
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/02/2014
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1114
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Query!
Recruitment hospital [1]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Merewether
Query!
Recruitment hospital [2]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Keswick
Query!
Recruitment hospital [3]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Box Hill
Query!
Recruitment hospital [4]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Parkville
Query!
Recruitment postcode(s) [1]
0
0
2291 - Merewether
Query!
Recruitment postcode(s) [2]
0
0
5035 - Keswick
Query!
Recruitment postcode(s) [3]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [4]
0
0
3050 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Hawaii
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Idaho
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Iowa
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Kansas
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Kentucky
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Louisiana
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Maryland
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Minnesota
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Missouri
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Montana
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Nebraska
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Nevada
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New Hampshire
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
New York
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
North Carolina
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Ohio
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Oregon
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
South Carolina
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Tennessee
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Texas
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Utah
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Washington
Query!
Country [28]
0
0
Belgium
Query!
State/province [28]
0
0
Brussels
Query!
Country [29]
0
0
Belgium
Query!
State/province [29]
0
0
Edegem
Query!
Country [30]
0
0
Belgium
Query!
State/province [30]
0
0
Huy
Query!
Country [31]
0
0
Belgium
Query!
State/province [31]
0
0
Sint-Niklaas
Query!
Country [32]
0
0
Brazil
Query!
State/province [32]
0
0
Fortaleza
Query!
Country [33]
0
0
Brazil
Query!
State/province [33]
0
0
Porto Alegre
Query!
Country [34]
0
0
Brazil
Query!
State/province [34]
0
0
São Paulo
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Alberta
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
Manitoba
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Nova Scotia
Query!
Country [38]
0
0
Canada
Query!
State/province [38]
0
0
Ontario
Query!
Country [39]
0
0
Canada
Query!
State/province [39]
0
0
Quebec
Query!
Country [40]
0
0
Croatia
Query!
State/province [40]
0
0
Osijek
Query!
Country [41]
0
0
Denmark
Query!
State/province [41]
0
0
Kobenhavn
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
La Rochelle
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Le Creuzot
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Paris
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Rouen
Query!
Country [46]
0
0
Greece
Query!
State/province [46]
0
0
Athens
Query!
Country [47]
0
0
Greece
Query!
State/province [47]
0
0
Chalkida
Query!
Country [48]
0
0
Greece
Query!
State/province [48]
0
0
Thessaloniki
Query!
Country [49]
0
0
Ireland
Query!
State/province [49]
0
0
Dublin
Query!
Country [50]
0
0
Israel
Query!
State/province [50]
0
0
Haifa
Query!
Country [51]
0
0
Israel
Query!
State/province [51]
0
0
Jerusalem
Query!
Country [52]
0
0
Israel
Query!
State/province [52]
0
0
Petah Tikva
Query!
Country [53]
0
0
Israel
Query!
State/province [53]
0
0
Petah Tiqva
Query!
Country [54]
0
0
Israel
Query!
State/province [54]
0
0
Tel Hashomer
Query!
Country [55]
0
0
Lithuania
Query!
State/province [55]
0
0
Jonava
Query!
Country [56]
0
0
Lithuania
Query!
State/province [56]
0
0
Kaunas
Query!
Country [57]
0
0
Netherlands
Query!
State/province [57]
0
0
Dordrecht
Query!
Country [58]
0
0
Netherlands
Query!
State/province [58]
0
0
Groningen
Query!
Country [59]
0
0
New Zealand
Query!
State/province [59]
0
0
Christchurch
Query!
Country [60]
0
0
New Zealand
Query!
State/province [60]
0
0
Wellington
Query!
Country [61]
0
0
Poland
Query!
State/province [61]
0
0
Gdansk
Query!
Country [62]
0
0
Poland
Query!
State/province [62]
0
0
Katowice
Query!
Country [63]
0
0
Poland
Query!
State/province [63]
0
0
Krakow
Query!
Country [64]
0
0
Poland
Query!
State/province [64]
0
0
Lubin
Query!
Country [65]
0
0
Poland
Query!
State/province [65]
0
0
Lublin
Query!
Country [66]
0
0
Poland
Query!
State/province [66]
0
0
Szczecin
Query!
Country [67]
0
0
Poland
Query!
State/province [67]
0
0
Warsaw
Query!
Country [68]
0
0
Slovakia
Query!
State/province [68]
0
0
Sturovo
Query!
Country [69]
0
0
South Africa
Query!
State/province [69]
0
0
Houghton
Query!
Country [70]
0
0
South Africa
Query!
State/province [70]
0
0
Pretoria
Query!
Country [71]
0
0
South Africa
Query!
State/province [71]
0
0
Somerset West
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
Alcala De Henares
Query!
Country [73]
0
0
Spain
Query!
State/province [73]
0
0
Alcira
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Barcelona
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Málaga
Query!
Country [76]
0
0
Spain
Query!
State/province [76]
0
0
Sevilla
Query!
Country [77]
0
0
Spain
Query!
State/province [77]
0
0
Seville
Query!
Country [78]
0
0
Spain
Query!
State/province [78]
0
0
Valencia
Query!
Country [79]
0
0
Sweden
Query!
State/province [79]
0
0
Alingsås
Query!
Country [80]
0
0
Sweden
Query!
State/province [80]
0
0
Helsingborg
Query!
Country [81]
0
0
Sweden
Query!
State/province [81]
0
0
Huddinge
Query!
Country [82]
0
0
Sweden
Query!
State/province [82]
0
0
Karlstad
Query!
Country [83]
0
0
United Kingdom
Query!
State/province [83]
0
0
Avon
Query!
Country [84]
0
0
United Kingdom
Query!
State/province [84]
0
0
Hampshire
Query!
Country [85]
0
0
United Kingdom
Query!
State/province [85]
0
0
Lancashire
Query!
Country [86]
0
0
United Kingdom
Query!
State/province [86]
0
0
Leicestershire
Query!
Country [87]
0
0
United Kingdom
Query!
State/province [87]
0
0
Scotland
Query!
Country [88]
0
0
United Kingdom
Query!
State/province [88]
0
0
Suffolk
Query!
Country [89]
0
0
United Kingdom
Query!
State/province [89]
0
0
Surrey
Query!
Country [90]
0
0
United Kingdom
Query!
State/province [90]
0
0
Wales
Query!
Country [91]
0
0
United Kingdom
Query!
State/province [91]
0
0
Glasgow
Query!
Country [92]
0
0
United Kingdom
Query!
State/province [92]
0
0
Northampton
Query!
Country [93]
0
0
United Kingdom
Query!
State/province [93]
0
0
Oxford
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Eli Lilly and Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is:
- To compare blood sugar control on LY2605541 with insulin glargine after 52 weeks of
treatment.
- To compare the rate of nocturnal low blood sugar episodes on LY2605541 with insulin
glargine during 52 weeks of treatment.
- To compare the number of participants on LY2605541 reaching blood sugar targets without
low blood sugar episodes at night to those taking insulin glargine after 52 weeks of
treatment.
- To compare the rate of low blood sugar episodes on LY2605541 with insulin glargine
during 52 weeks of treatment
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01454284
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Query!
Address
0
0
Eli Lilly and Company
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01454284
Download to PDF